Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institution: Fudan University Shanghai Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: tislelizumab, donafenib, GEMOX, gemcitabine, oxaliplatin, advanced biliary tract cancer, cholangiocarcinoma, gallbladder cancer, first-line therapy, immune checkpoint inhibitors, combination chemotherapy, objective response rate, progression-free survival, treatment safety, PD-1/PD-L1 blockade, tyrosine kinase inhibitors
Open Access status: closed
OpenAlex ID: W7162575554
